Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China · Delayed Price · Currency is CNY 270.83
-1.16 (-0.43%)
Aug 28, 2026, 4:00 PM EDT
SHA:688506 Revenue
Sichuan Biokin Pharmaceutical had revenue of 92.75M CNY in the quarter ending June 30, 2026, a decrease of -10.61%. This brings the company's revenue in the last twelve months to 2.54B, up 474.87% year-over-year. In the year 2025, Sichuan Biokin Pharmaceutical had annual revenue of 2.52B, down -56.72%.
Revenue (ttm)
2.54B
Revenue Growth
+474.87%
P/S Ratio
44.09
Revenue / Employee
738.57K
Employees
3,434
Market Cap
111.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.52B | -3.30B | -56.72% |
| Dec 31, 2024 | 5.82B | 5.26B | 936.31% |
| Dec 31, 2023 | 561.87M | -141.41M | -20.11% |
| Dec 31, 2022 | 703.28M | -93.45M | -11.73% |
| Dec 31, 2021 | 796.73M | -215.98M | -21.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 44.00B |
| Shanghai Fosun Pharmaceutical (Group) | 42.59B |
| Yunnan Baiyao Group Co.,Ltd | 41.81B |
| China Resources Sanjiu Medical & Pharmaceutical | 31.81B |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 31.32B |
| Zhejiang NHU Company | 24.28B |
| Humanwell Healthcare (Group) | 23.96B |
| Beijing Tongrentang | 16.64B |
Sichuan Biokin Pharmaceutical News
- 5 days ago - Sichuan Biokin Pharmaceutical Quarterly report: Q2 2026 - Filings